ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
This Study is
No Longer Enrolling
Child to Adult
II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Treatment
Childrens Hospital Colorado
Protocol Number: 17-1045
More information available at ClinicalTrials.gov: NCT02867592
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers